FDA Approved: UPTRAVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for UPTRAVI (selexipag) from Actelion Pharmaceuticals US, Inc., indicating an updated label or expanded indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Uptravi (selexipag)

Snippet

SUPPL AP for UPTRAVI (SELEXIPAG)